Skip to main content
Clinical Trials/NCT03245320
NCT03245320
Terminated
Not Applicable

A Post-Market Observational Study to Evaluate Performance and Safety of the TITAN™ Total Shoulder System

Smith & Nephew, Inc.2 sites in 1 country50 target enrollmentStarted: March 20, 2017Last updated:

Overview

Phase
Not Applicable
Status
Terminated
Enrollment
50
Locations
2
Primary Endpoint
Implant survival at 2 years

Overview

Brief Summary

A post market, non-randomized, multi-center, open-label,clinical study using survivorship to study the safety and efficacy of the Integra® TITAN™ Total Shoulder System 1.0 (TAS) when used for total shoulder arthroplasty.

Detailed Description

Observational, multi-center, post-market study to provide data on the performance and safety of the TITAN™ Total Shoulder System. The study will enroll patients that underwent total shoulder arthroplasty with the TITAN™ Total Shoulder System per standard of care less than 5 years ago. Available retrospective data up to the 2-year time point will be collected, per the study protocol, from medical record reviews. Prospective observational data will be collected from the time of patient enrollment during the following postoperative clinical visits: 1 year, 2 years, 5 years and 10 years post-surgery.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject has undergone shoulder arthroplasty with the first generation TITAN Total Shoulder System.
  • The first generation TITAN Total Shoulder System is still intact and the subject has not received any revision surgeries involving the TITAN Total Shoulder System.
  • Subject is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures.

Exclusion Criteria

  • Subject, in the opinion of the PI, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study such as mental illness, or drug or alcohol abuse.
  • Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits.

Outcomes

Primary Outcomes

Implant survival at 2 years

Time Frame: 2 years

Implant survivorship is defined as absence of device removal or revision of one or more of the implant component(s).

Secondary Outcomes

  • Implant survival .(5 and 10 years)
  • Radiographic assessment(2, 5, and 10 years)
  • Relative change in Quality Of Life (EQ-5D) compared to baseline(2, 5, and 10 years)
  • Relative change of American Shoulder and Elbow Surgeon Score (ASES) compared to baseline(2, 5, and 10 years)
  • Relative change of Range of Motion (ROM) compared to baseline(2, 5, and 10 years)
  • Relative change in Quality Of Life (SF-12V1) compared to baseline(2, 5, and 10 years)
  • Relative change of PENN Pain and Function Score (PENN) compared to baseline(2, 5, and 10 years)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials